迪亚弗罗巴克特尼降低剂与酸协同作用,降低肺腺癌小鼠的瘤负担

相关实验视频

Updated: Jul 1, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

Yalan Ni^1,2, Rui Li^1,2, Xiaoyu Shen^1,3

¹Department of Oncology, Affiliated Children's Hospital of Jiangnan University, Wuxi, Jiangsu, China.

mSystems

|March 14, 2024

概括

将Diaphorobacter nitroreducens与oxaliplatin相结合,可以增强小鼠肺腺癌 (LADC) 的治疗效果. 这种新的方法修改了肠道微生物群和瘤免疫力,为LADC治疗提供了一个有希望的策略.

科学领域:

微生物学和免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

肺腺癌 (LADC) 是全球癌症死亡的主要原因.
奥克萨利普拉丁是LADC的关键化疗剂,但其疗效受到副作用和耐药性的限制.
肠道微生物群调节正在成为改善化疗结果的策略.

研究的目的:

在LADC的小鼠模型中,研究Diaphorobacter nitroreducens (D. nitroreducens) 与氧沙结合的抗癌作用.
探索这种联合治疗对肠道微生物群组成和瘤免疫透的影响.
评估D. nitroreducens作为LADC化疗的潜在辅助疗法.

主要方法:

携带瘤的小鼠接受了D. 降剂,氧化或其组合的治疗.
用16S rRNA基因高通量测序分析了肠道微生物组成.
瘤免疫细胞透被通过免疫光检测评估.

主要成果:

丁降解剂和氧沙的组合表明,比单独使用氧沙的瘤抑制显著更强.
组合疗法增加了肠道微生物群中的有益细菌,包括Lactobacillus和Akkermansia的丰富性.
结合治疗后,瘤组织显示巨细胞透率增加和调控性T细胞比例下降.

结论:

迪亚弗罗巴克特尼降低剂与氧沙胺协同作用,以增强LADC的抗癌作用.
组合疗法调节肠道微生物群和瘤免疫微环境,有助于改善治疗结果.
这项研究强调了D. nitroreducens作为LADC辅助疗法的潜力,准肠道微生物群-免疫细胞-LADC轴.

关键词:

16S rRNA 基因测序的基因测序 D. 降低了的含量我们的肠道微生物群.免疫透免疫透是什么?肺部腺癌的癌症.

相关概念视频

01:27

Combined Effects of Drugs: Synergism

3.9K

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

3.9K

02:49

Cancer Therapies

7.7K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

7.7K

02:50

Combination Therapies and Personalized Medicine

4.9K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

4.9K

02:57

Targeted Cancer Therapies

7.6K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...